Notably, the lipid‐lowering effects of SREBP2 inhibition are independent of a functional LDL receptor, highlighting the potential of acute hepatic SREBP2 depletion as a promising therapeutic strategy for managing homozygous familial hypercholesterolemia. The gene discussed is LDLR; the disease is familial hypercholesterolemia.